



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

August 30, 2023

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
**Mumbai 400 001**

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) **Mumbai 400 051**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Please find enclose herewith the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.

Thanking you,

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

### Annexure

#### Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Details of Investment
A	Name of the target entity, details in brief such as size, turnover etc.	ISCA, Inc., a Delaware Corporation had a turnover of \$9,338,426 in the last fiscal year ending on December 31, 2022.
B	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
C	Industry to which the entity being acquired belongs	Pest control for agriculture
D	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Strategic investment for bio control of pest
E	Brief details of any governmental or regulatory approvals required for the acquisition	Under Foreign Exchange Management (Overseas Investment) Rules, 2022 and subject to applicable regulatory approvals, if any.
F	Indicative time period for completion of the acquisition;	31 August 2023
G	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
H	Cost of acquisition or the price at which the shares are acquired	Overall cost of acquisition is USD 2 million
I	Percentage of shareholding / control acquired and / or number of shares acquired	5.79% (Increase is on account of anti-dilution shares receivable to protect the investment value of approximately USD 2 million already made, with only a nominal cash outflow now)



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Sl. No.	Particulars	Details of Investment
J	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<ol style="list-style-type: none"><li><b>Brief background:</b> ISCA, Inc. aims to manufacture pesticides that disrupt mating patterns in pests and thereby control insect populations.</li><li><b>Line of business:</b> Pest control for agriculture</li><li><b>Date of incorporation:</b> 7<sup>th</sup> November, 2019</li><li><b>Turnover of last 3 years ending December 31 (in US\$):</b>  Turnover as of December 31, 2022: \$9,338,426  Turnover as of December 31, 2021: \$9,016,200  Turnover as of December 31, 2020: \$9,714,611</li><li><b>Country in which the acquired entity will have presence:</b> USA</li></ol>